Helios (Santa Fe, NM) unveiled the results of its third clinical trial for EstroG-100, which demonstrated the positive effects the supplement has on women in various stages of menopause.

Evaluating 70 women, 10 of 12 symptoms evaluated significantly improved over the three-month time frame, or, results duplicated the USA-based second clinical trial utilizing the same protocols ( Kupperman Menopause Index or called the KMI), reported Helios.

Michael Jeffers, North American partner of EstroG-100, Helios CORP, said the nutritional industry doesn’t really demand evidence of performance much beyond one human clinical study and a few of the larger companies prefer two human clinical studies.

“Helios CORP has always strived for excellence when defining proof of performance with at least two ‘independently tested’ human clinical trial studies, and thus we initiated our effort to add a third, placebo-controlled, double-blind, randomized human clinical trial for the menopause ingredient called EstroG-100. We wanted to raise the bar further in the menopause category,” said Jeffers.

The first double-blind placebo controlled trial using EstroG-100 showed six times better results in menopausal symptoms over the control group during a 12-month time frame, with no weight gain, and the second human clinical trial found Estro-G100 to significantly improve night sweats, hot flashes, vaginal dryness, insomnia, depression and joint discomfort in 61 menopausal participants over three months (also utilizing the KMI), according to Helios.

The third clinical trial, focused on pre-, peri-, and post-menopausal women, and evaluated to determine if the oral supplementation of EstroG-100 could improve symptoms such as vasomotor, paresthesia (numbness or tingling), trouble sleeping, nervousness, melancholia, vertigo, fatigue, joint or muscle pain, headache, palpitation, formication (the sensation of crawling on the skin) and vaginal dryness.

“As far as we know there are no menopause ingredients in the nutra market today that bear a comparable Phase II trial and Phase III human clinical trial study with similar protocols. Our thinking and intent is to provide our customers with the opportunity to make stronger structure function claims on the label of their finished products using our EstroG-100,” said Jeffers, adding “Helios CORP is pleased to be at the forefront of game changing technology for the 45 million USA women in menopause.”

For more information, visit www.helioscorp.net.